Stock Trading Canary

United States · SEC Form 4 · Snapshot date: 2026-10-19 · Built: 2026-10-19 · 中文

← United States · Coverage record

US · SEC FORM 4

Q32 Bio Inc.

QTTB · Nasdaq · CIK 0001661998 · Healthcare · Biotechnology

INSIDER SIGNAL

69.0 / 100

2 buyers · 4 purchase transaction lines · $30.0M gross purchase

WHY THIS SIGNAL?

Buyer breadthLow
Purchase sizeStrong
RoleStrong
RecencyLow
ConvictionStrong
Score anatomy

Each bar shows the contribution to the current score; the weights and formula stay unchanged.

Cluster+14.0 / 35
Purchase size+24.2 / 25
Role+20.0 / 20
Recency+0.9 / 10
Conviction+9.9 / 10

What is holding the score back?

  • ⚠ Cluster breadth is moderate · 2 insider(s), not 4+
  • ⚠ Purchase activity is becoming less recent
  • ✓ Role scores high · most senior buyer: Director,TenPercentOwner

Purchase-size comments are relative to the model scale. Average daily volume is a separate market-context diagnostic.

US-v1.2 ranks qualifying equity purchases under the current 180-day rules. The score is a research priority, not a return forecast or probability. Backtests have not shown that a higher US score is followed by better returns.

Purchase breadth & concentration

QUALIFYING BUYERS2
PURCHASE CONCENTRATION50%Largest buyer: Xu Diyong · $15.0M
CLUSTER BUYING · 15D2 insidersPeak activity: 2026-05-28–2026-05-28

Roles in the peak window: Director,TenPercentOwner. Concentration uses priced qualifying P lines only and does not change the saved score.

Insider activity timeline

Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.

AprMayJunJulAugSepOct
Morrison Jodie PopeCEO
○▼▼
Kalowski LeeCFO and President
○▼▼
Violette Shelia M.Chief Scientific Officer
○▼▼
Xu DiyongDirector,TenPercentOwner
●
ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCDirector,TenPercentOwner
●
Manke IsaacDirector
○
● Purchase▼ Sale○ Other

—

SIGNAL HISTORY

69.0 / 100

Latest recorded score

→ +0.0 ptsversus the previous recorded snapshot
  1. 69.0
  2. 69.0
  3. 69.0
  4. 69.0
  5. 69.0

Only scores saved when a full US scoring run completed are shown; gaps are not reconstructed.

Recent Form 4 activity

4Purchases
11Sales
7Other Form 4 lines
20SEC filings · 365 days
BUYING4 qualifying P line(s) · 180 days
SELLING6 sale line(s) · context only
OTHER4 exercise / withholding / award / gift / other lines
10b5-1 / PLANNEDNot detected in parsed evidence

P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.

Market context

Market context provides additional background on recent price performance and risk. It does not affect the Insider Signal.

Price performance

1M
-22.2%
3M
-61.0%
6M
+65.1%
12M
+178.9%

Volatility & liquidity

Volatility
175.3%
Beta
—
Avg daily value
USD 7.7M

Valuation

Market cap
USD 248.3M
P/E
8.3×

Fundamentals

Profit margin
55.5%
ROE
70.9%
Industry
Biotechnology

Market data

Price data up to: 2026-10-11 · Price source: OpenBB/yfinance; volume from price cache (yfinance) · From SEC filings: Market cap, P/E, Profit margin, ROE · Fiscal year ended: 2025-12-31 · Market cap is the shares outstanding stated on the filing cover multiplied by the latest close. Share count date: 2026-08-03 · Status: PASS

Short interest

Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.

Shares short
4,671,943
Previous report
3,772,651
Avg daily volume
1,084,552
Days to cover
4.3

FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.

Historical equity purchases

Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.

Transaction dateReporting ownerTypeSecuritySharesAvg. priceApprox. valueSource
2026-05-28Xu DiyongPurchase (P)Common Stock1,875,000USD 8.00USD 15,000,000SEC filing ↗
2026-05-28ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock1,875,000USD 8.00USD 15,000,000SEC filing ↗

Form 4 evidence

22 transaction lines in the latest 365-day window; 130 in local history.

DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-06Violette Shelia M.Sale (S)Common Stock917USD 8.32USD 7,629SEC filing ↗
2026-10-06Morrison Jodie PopeSale (S)Common Stock3,221USD 8.32USD 26,798SEC filing ↗
2026-10-06Kalowski LeeSale (S)Common Stock1,301USD 8.32USD 10,824SEC filing ↗
Show recent Form 4 evidence (20 grouped rows)
DateOwnerTypeSecuritySharesAvg. priceApprox. valueSource
2026-10-06Violette Shelia M.Sale (S)Common Stock917USD 8.32USD 7,629SEC filing ↗
2026-10-06Morrison Jodie PopeSale (S)Common Stock3,221USD 8.32USD 26,798SEC filing ↗
2026-10-06Kalowski LeeSale (S)Common Stock1,301USD 8.32USD 10,824SEC filing ↗
2026-08-25Violette Shelia M.Sale (S)Common Stock2,798USD 16.56USD 46,335SEC filing ↗
2026-08-25Morrison Jodie PopeSale (S)Common Stock9,845USD 16.56USD 163,033SEC filing ↗
2026-08-25Kalowski LeeSale (S)Common Stock3,972USD 16.56USD 65,776SEC filing ↗
2026-07-16Violette Shelia M.Award / grant (A)Common Stock37,500USD 0.00USD 0SEC filing ↗
2026-07-16Morrison Jodie PopeAward / grant (A)Common Stock132,000USD 0.00USD 0SEC filing ↗
2026-07-16Kalowski LeeAward / grant (A)Common Stock53,250USD 0.00USD 0SEC filing ↗
2026-06-30Manke IsaacOption exercise / conversion (M)Common Stock53,521USD 2.80USD 149,859SEC filing ↗
2026-05-28Xu DiyongPurchase (P)Common Stock1,875,000USD 8.00USD 15,000,000SEC filing ↗
2026-05-28ORBIMED ADVISORS LLC; OrbiMed Capital GP VII LLC; OrbiMed Genesis GP LLCPurchase (P)Common Stock1,875,000USD 8.00USD 15,000,000SEC filing ↗
2026-02-25Violette Shelia M.Sale (S)Common Stock2,815USD 4.51USD 12,696SEC filing ↗
2026-02-25Morrison Jodie PopeSale (S)Common Stock9,896USD 4.51USD 44,631SEC filing ↗
2026-02-25Kalowski LeeSale (S)Common Stock3,995USD 4.51USD 18,017SEC filing ↗
2026-02-24Violette Shelia M.Award / grant (A)Common Stock37,500USD 0.00USD 0SEC filing ↗
2026-02-24Morrison Jodie PopeAward / grant (A)Common Stock132,000USD 0.00USD 0SEC filing ↗
2026-02-24Kalowski LeeAward / grant (A)Common Stock53,250USD 0.00USD 0SEC filing ↗
2025-12-02Morrison Jodie PopeSale (S)Common Stock22,506USD 3.46USD 77,871SEC filing ↗
2025-12-02Kalowski LeeSale (S)Common Stock9,072USD 3.46USD 31,389SEC filing ↗

Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.

Snapshot & identity

Snapshot date2026-10-19
Ranking versionUS-v1.2
Data qualityPASS ELIGIBLE · —
TickerQTTB
CIK0001661998
SectorHealthcare
IndustryBiotechnology Yahoo Finance
SEC SIC2834 Pharmaceutical Preparations
ExchangeNasdaq

Data coverage

Local Form 4 history130 transaction lines from 2020-01-02 to 2026-10-06
4 P purchase lines · 70 S sale lines · 56 other lines
SEC company submissionsOpen SEC filings ↗

Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.